Thrombolysis – Medxy AI

Tenecteplase Improves 90-Day Functional Outcomes in Basilar Artery Occlusion Within a 24-Hour Window: Results from TRACE-5

By MedXY 02/16/2026

The TRACE-5 trial demonstrates that tenecteplase significantly improves functional outcomes for patients with basilar artery occlusion within 24 hours of onset, offering a safe and effective extension of the therapeutic window for this high-mortality condition.

Neurology news Radiology

Expanding the Thrombolysis Window: Tenecteplase Improves Outcomes in Late-Window Non-Large Vessel Occlusion Stroke

By MedXY 02/08/2026

The OPTION trial reveals that tenecteplase administered 4.5 to 24 hours post-stroke in patients with non-large vessel occlusion and salvageable tissue significantly improves functional recovery, although it carries a higher risk of symptomatic intracranial hemorrhage compared to standard care.

Neurology news Ophthalmology

Tenecteplase Fails to Improve Visual Outcomes in Acute Central Retinal Artery Occlusion: Results from the TenCRAOS Trial

By MedXY 02/02/2026

The TenCRAOS trial demonstrated that intravenous tenecteplase administered within 4.5 hours of acute central retinal artery occlusion does not improve vision recovery compared to aspirin and carries significant safety risks, including fatal intracranial hemorrhage.

Clinical Updates Neurology news

急性虚血性脳卒中における補助的静注アルガトロバンまたはエプチフィバチド投与：MOST無作為化臨床試験によるエビデンス

By MedXY 12/11/2025

Recent multi-site randomized evidence demonstrates that adding intravenous argatroban or eptifibatide to standard thrombolysis within 3 hours of stroke onset does not improve functional recovery and is associated with increased mortality, including in patients undergoing mechanical thrombectomy.

Neurology news

Evaluating Alteplase Use in Minor Ischemic Stroke: Insights from a Nationwide Chinese Registry

By MedXY 10/29/2025

A nationwide Chinese registry analysis reveals no overall benefit of intravenous alteplase in minor ischemic stroke but suggests select subgroups, especially those with disabling symptoms or higher NIHSS scores, may experience improved functional outcomes.

Ophthalmology Specialties

Intravenous Alteplase Versus Oral Aspirin in Acute Central Retinal Artery Occlusion: Insights from the THEIA Phase 3 Trial and Contextual Evidence

By MedXY 10/22/2025

THEIA trial evaluated intravenous alteplase against oral aspirin in acute CRAO within 4.5 hours; no significant visual improvement difference was found, emphasizing the need for further research and meta-analyses to clarify thrombolysis benefits.

Emergency Medicine Neurology Rehabilitation Medicine Specialties

Evaluating Telestroke’s Impact on Acute Ischemic Stroke Treatment Timeliness and Outcomes

By MedXY 10/22/2025

Telestroke evaluation increases thrombolysis rates but is associated with longer treatment times and delays in patient transfers in acute ischemic stroke, highlighting the need to address modifiable treatment delays.

Neurology news Specialties

Extending the Therapeutic Window: Alteplase Use 4.5 to 24 Hours After Ischemic Stroke in the HOPE Trial

By MedXY 09/03/2025

The HOPE trial demonstrates that intravenous alteplase administered 4.5 to 24 hours after ischemic stroke onset improves functional independence in patients with salvageable brain tissue, despite increased risk of symptomatic intracranial hemorrhage.

Neurology news Specialties

Thrombolysis Before Thrombectomy May Raise ICH Risk After Stroke: A Comprehensive Review of Recent Evidence

By MedXY 08/19/2025

A meta-analysis of over 2000 stroke patients found that intravenous thrombolysis (IVT) before endovascular treatment (EVT) modestly increases intracranial hemorrhage (ICH) risk, especially in patients with elevated glucose and blood pressure, though functional benefits may still outweigh risks.